



(43) International Publication Date
26 May 2016 (26.05.2016)

(10) International Publication Number
WO 2016/079076 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C07K 16/46 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2015/076739

(22) International Filing Date:

17 November 2015 (17.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14194147.6 20 November 2014 (20.11.2014) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road, 8th Floor, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BACAC, Marina**; Holderbachweg 21, 8046 Zuerich (CH). **BRUENKER, Peter**; Burgwiesenstrasse 3c,

8335 Hittnau (CH). **FREIMOSER-GRUNDSCHÖBER, Anne**; Neunbrunnenstrasse 76, 8050 Zuerich (CH). **HOSSE, Ralf**; Schmiedstrasse 8, 6330 Cham (CH). **KLEIN, Christian**; Chapfstrasse 26B, 8906 Bonstetten (CH). **MOESSNER, Ekkehard**; Felsenburgweg 5, 8280 Kreuzlingen (CH). **UMANA, Pablo**; Felsenrainstrasse 28, 8832 Wollerau (CH). **WEINZIERL, Tina**; Urdorferstrasse 93, 8952 Schlieren (CH).


(74) Agent: **BRODBECK, Michel**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AGIANT FOLR1 AND CD3

Fig. 1A



(57) Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))